



“Support for the medical transition of youth living with neurological conditions is a small but critical acknowledgement that youth should not simply survive into adulthood: they should thrive as adults.”¹

– Child Neurology Foundation

Transitioning TSC patients with neurologic manifestations from pediatric to adult care

As a chronic disease with an unpredictable course, tuberous sclerosis complex (TSC) requires lifelong, ongoing surveillance²

- > **TSC-associated neuropsychiatric disorders (TAND)** and epilepsy can be present throughout life^{2,3}
- > **Renal manifestations** require significantly more monitoring and intervention as patients get older²
- > **Lymphangiomyomatosis** develops in adults and can cause serious pulmonary issues²

Proper transitioning from pediatric to adult care is critical for TSC patients⁴

Transition planning can help to^{2,4}:

- > Prevent gaps in care
- > Avert preventable health crises
- > Avoid duplicative tests and services
- > Ensure appropriate monitoring and symptom management to prevent more costly medical complications

Brought to you by Novartis Pharmaceuticals Corporation, in partnership with



The Child Neurology Foundation Guidelines on Transitioning Youth to Adult Health Care⁴

The following guidelines for child neurology teams are based on a consensus statement issued by the Neurology Transition Consensus panel, an interdisciplinary team of medical professionals, neurology patients, and family members of patients.

BY AGE 13

- Discuss the expected transition to adult health care with youth and caregiver(s)

BEGINNING ~AGE 13

- Assess youth's self-management skills annually
 - > Document assessments
 - > Communicate to other health care providers
- Work with youth and caregiver(s) in phased transition planning, education, and transfer readiness annually
- Include youths with intellectual disabilities in the process, with discussions targeted to caregiver(s)

BEGINNING AT AGE 14

- Begin discussion regarding youth's legal competency (eg, need for legal guardianship, powers of attorney)
- Begin developing transition plan; child neurology team is responsible for neurology content
- Ensure plan is based on collaboration with youth, caregiver(s), health care providers, school personnel, legal services (as needed)

1 TO 2 YEARS BEFORE TRANSITION

- Work with youth and caregiver(s) to identify appropriate adult care provider(s) for the neurologic condition(s)

AT TIME OF TRANSITION

- Send adult provider(s) a transfer packet, including the transition plan and medical summary
- Confirm adult provider(s) has agreed to accept patient
- Document the transfer



Visit www.neurology.org for a free copy of the complete guidelines.

AT YEARLY VISIT BEFORE THE TRANSFER OF CARE, PLAN TO ADDRESS:

- > Current medical condition
- > Current medications/potential side effects
- > Signs and symptoms of concern
- > Genetic counseling
- > Issues of puberty and sexuality
- > Driving, alcohol and substance use, other risks
- > Emotional/psychological concerns and wellness

THESE GUIDELINES ARE ENDORSED BY AND/OR ALIGNED WITH:

American Academy of Neurology

American Epilepsy Society

Child Neurology Society

American Academy of Pediatrics

References: 1. Transitioning youth to the adult healthcare system. Child Neurology Foundation website. <http://www.childneurologyfoundation.org/advocates/transitioning-youth-to-the-adult-healthcare-system/>. Accessed November 16, 2016. 2. Krueger DA, Northrup H; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. *Pediatr Neurol*. 2013;49(4):255-265. 3. French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3 randomised, double-blind, placebo-controlled study. *Lancet*. 2016;388:2153-2163. 4. Brown LW, Camfield P, Caper M, et al. The neurologist's role in supporting transition to adult health care: a consensus statement. *Neurology*. 2016;87(8):834-840.



Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

